Total Payments
$8,023
2024 Payments
$545.23
Companies
30
Transactions
191
Medicare Patients
3,058
Medicare Billing
$741,725
Payment Breakdown by Category
Food & Beverage$5,326 (66.4%)
Travel$1,620 (20.2%)
Research$992.73 (12.4%)
Education$83.70 (1.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,326 | 177 | 66.4% |
| Travel and Lodging | $1,620 | 2 | 20.2% |
| Unspecified | $992.73 | 7 | 12.4% |
| Education | $83.70 | 5 | 1.0% |
Payments by Type
General
$7,030
184 transactions
Research
$992.73
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Roche Products Limited | $2,480 | 3 | $0 (2023) |
| GlaxoSmithKline, LLC. | $1,314 | 18 | $0 (2024) |
| Amgen Inc. | $852.50 | 32 | $0 (2024) |
| Fresenius USA Marketing, Inc. | $463.27 | 20 | $0 (2024) |
| Horizon Therapeutics plc | $423.11 | 13 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $412.39 | 16 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $388.41 | 10 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $216.77 | 11 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $191.60 | 5 | $0 (2024) |
| Relypsa, Inc. | $158.43 | 7 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $545.23 | 22 | Amgen Inc. ($309.82) |
| 2023 | $3,112 | 23 | Roche Products Limited ($2,480) |
| 2022 | $615.33 | 28 | CALLIDITAS THERAPEUTICS US INC. ($123.53) |
| 2021 | $733.44 | 23 | GlaxoSmithKline, LLC. ($182.15) |
| 2020 | $138.80 | 8 | Horizon Therapeutics plc ($37.97) |
| 2019 | $1,843 | 39 | GlaxoSmithKline, LLC. ($992.73) |
| 2018 | $387.81 | 18 | Amgen Inc. ($194.30) |
| 2017 | $646.58 | 30 | Amgen Inc. ($216.95) |
All Payment Transactions
191 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/09/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $4.22 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/04/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Education | In-kind items and services | $24.61 | General |
| Category: Nephrology | ||||||
| 12/04/2024 | AKEBIA THERAPEUTICS INC | Auryxia (Drug), Vafseo | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: Nephrology | ||||||
| 11/18/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $28.48 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/13/2024 | Novo Nordisk Inc | Rivfloza (Drug) | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: Rare Disease | ||||||
| 11/04/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $27.40 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/25/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $14.70 | General |
| 10/23/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $25.87 | General |
| Category: NEPHROLOGY | ||||||
| 10/18/2024 | Amgen Inc. | Aranesp (Biological), Parsabiv, TAVNEOS | Food and Beverage | In-kind items and services | $27.10 | General |
| Category: Nephrology | ||||||
| 09/27/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: IMMUNOLOGY | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/06/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $59.07 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/22/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $31.45 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/15/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: Inflammation | ||||||
| 07/08/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: IMMUNOLOGY | ||||||
| 06/19/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 06/07/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $5.21 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/24/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $5.83 | General |
| Category: Inflammation/Rare Disease | ||||||
| 04/22/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $73.34 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/21/2024 | Fresenius USA Marketing, Inc. | — | Food and Beverage | In-kind items and services | $21.94 | General |
| 01/19/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $26.42 | General |
| Category: NEPHROLOGY | ||||||
| 12/21/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $21.57 | General |
| Category: Rare Disease | ||||||
| 12/13/2023 | Fresenius USA Marketing, Inc. | KORSUVA (Drug) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: KORSUVA a Kappa opioid receptor agonist for pruritus companied with chronic kidney disease CKD-aP | ||||||
| 12/08/2023 | Calliditas Therapeutics US Inc. | TARPEYO (Drug) | Education | Cash or cash equivalent | $13.60 | General |
| Category: Nephrology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | GlaxoSmithKline, LLC. | $992.73 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 497 | 1,076 | $360,825 | $143,583 |
| 2022 | 12 | 717 | 1,425 | $420,860 | $173,696 |
| 2021 | 12 | 941 | 1,808 | $483,272 | $223,431 |
| 2020 | 12 | 903 | 1,874 | $515,977 | $201,015 |
Total Patients
3,058
Total Services
6,183
Medicare Billing
$741,725
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 46 | 327 | $206,010 | $85,585 | 41.5% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 18 | 67 | $35,175 | $14,524 | 41.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 150 | 248 | $42,050 | $12,375 | 29.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 100 | 190 | $23,750 | $11,339 | 47.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 54 | 85 | $18,050 | $5,098 | 28.2% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 15 | 19 | $9,975 | $3,870 | 38.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 31 | 39 | $6,825 | $3,299 | 48.3% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 37 | 55 | $8,250 | $2,989 | 36.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $4,180 | $1,638 | 39.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $3,060 | $1,483 | 48.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 14 | $3,500 | $1,383 | 39.5% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 50 | 326 | $205,380 | $88,577 | 43.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 153 | 295 | $36,875 | $16,018 | 43.4% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2022 | 23 | 69 | $36,225 | $15,344 | 42.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 159 | 268 | $40,400 | $14,673 | 36.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 70 | 101 | $17,675 | $7,938 | 44.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 51 | 52 | $18,200 | $7,294 | 40.1% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 73 | 121 | $18,150 | $6,688 | 36.9% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 18 | 26 | $13,650 | $5,965 | 43.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 71 | 118 | $23,675 | $5,607 | 23.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 21 | 21 | $3,570 | $2,418 | 67.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 12 | 12 | $3,060 | $1,697 | 55.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 16 | 16 | $4,000 | $1,476 | 36.9% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 55 | 312 | $196,560 | $85,726 | 43.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 106 | 197 | $39,700 | $24,683 | 62.2% |
About Dr. Michael Casey, M.D
Dr. Michael Casey, M.D is a Nephrology healthcare provider based in Raleigh, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003894056.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Casey, M.D has received a total of $8,023 in payments from pharmaceutical and medical device companies, with $545.23 received in 2024. These payments were reported across 191 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($5,326).
As a Medicare-enrolled provider, Casey has provided services to 3,058 Medicare beneficiaries, totaling 6,183 services with total Medicare billing of $741,725. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Raleigh, NC
- Active Since 01/09/2006
- Last Updated 09/11/2024
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1003894056
Products in Payments
- KRYSTEXXA (Biological) $681.89
- Parsabiv (Biological) $401.11
- JYNARQUE (Drug) $334.37
- BENLYSTA (Biological) $321.21
- Velphoro (Drug) $268.44
- Veltassa (Drug) $218.86
- LUPKYNIS (Drug) $191.60
- KORSUVA (Drug) $158.75
- TARPEYO (Drug) $137.13
- FARXIGA (Drug) $121.22
- Auryxia (Drug) $114.66
- Kerendia (Drug) $114.27
- ULTOMIRIS (Biological) $92.89
- System One (Device) $90.00
- ACTHAR (Biological) $81.51
- LOKELMA (Drug) $78.57
- SAMSCA (Drug) $78.02
- FABRY-DISEASE (Drug) $73.77
- Tavneos (Drug) $58.26
- AURYXIA (Drug) $51.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Raleigh
Jeffrey Hoggard, M.d, M.D
Nephrology — Payments: $100,306
Nephrology $100,306
Dr. Sammy Moghazi, M.d, M.D
Nephrology — Payments: $55,439
Nephrology $55,439
Dr. Libbie Mckenzie, Md, MD
Nephrology — Payments: $34,174
Nephrology $34,174
Karn Gupta, Md, MD
Nephrology — Payments: $11,108
Nephrology $11,108
Dr. Phillip Timmons, M.d, M.D
Nephrology — Payments: $6,018
Nephrology $6,018
Michael Oliverio, M.d, M.D
Nephrology — Payments: $5,072
Nephrology $5,072